Global Healthcare Industry M&A and Capital Market Review Q1 2025

This report provides an analysis of the global healthcare mergers and acquisitions (M&A) and capital market landscape for the first quarter of 2025. It outlines a slowdown in deal activity as investors adopt a cautious approach amidst market volatility and geopolitical tensions. The report details how private equity players are focusing on bolt-on acquisitions while strategic buyers are prioritizing mid-market transactions. The document highlights the impact of pricing pressures in the pharmaceutical sector and the challenges posed by reduced reimbursements on valuations. Additionally, it discusses the trends in healthcare funding, noting a significant slowdown in the Debt Capital Market due to increased market volatility. The report also emphasizes the importance of environmental, social, and governance (ESG) factors in M&A, suggesting that companies with strong ESG profiles may benefit from lower capital costs. Looking ahead, the report anticipates a potential increase in deal activity, particularly in the pharma and biotech sectors, driven by available capital and a need for innovation.